![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/06\/1782790389_902_logo.jpg\"){kind=logo}
\u00a0<\/p>\n\u00a0<\/p>\n
UNITED STATES<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
Washington, D.C. 20549<\/p>\n
\u00a0<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
FORM 6-K<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
REPORT OF FOREIGN PRIVATE ISSUER<\/p>\n
\u00a0<\/p>\n
Pursuant to Rule 13a-16 or 15d-16<\/p>\n
of the Securities Exchange Act of 1934<\/p>\n
\u00a0<\/p>\n
June 29, 2026<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
NOVO NORDISK A\/S<\/p>\n
\u00a0(Exact name
\nof Registrant as specified in its charter)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Novo All\u00e9 1<\/p>\n
DK- 2880, Bagsvaerd<\/p>\n
Denmark<\/p>\n
(Address of principal executive offices)<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
Indicate by check mark whether the registrant files or will file annual reports under
\ncover of Form 20-F or Form 40-F<\/p>\n
\u00a0<\/p>\n
Form 20-F \u2612\u00a0\u00a0\u00a0\u00a0\u00a0
\n \u00a0\u00a0\u00a0\u00a0\u00a0Form 40-F \u2610<\/p>\n
\u00a0\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/06\/1782790390_615_ca.jpg\")
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Novo
\nNordisk A\/S \u2013 Share repurchase programme<\/p>\n
\u00a0<\/p>\n
Bagsv\u00e6rd, Denmark, 29 June
\n2026 \u2013 On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596\/2014
\nof the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016\/1052 of 8 March 2016
\n(the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during
\na 12-month period beginning 4 February 2026.<\/p>\n
\u00a0<\/p>\n
Under the programme initiated 6 May 2026, Novo Nordisk will
\nrepurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.<\/p>\n
\u00a0<\/p>\n
Since the announcement
\n22 June 2026, the following transactions have been made:<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Number
\n of<\/p>\n
B
\n shares<\/p>\n
Average<\/p>\n
purchase
\n price<\/p>\n
Transaction<\/p>\n
value,
\n DKK<\/p>\n
Accumulated, last announcement
\n 6,200,000
\n \u00a0
\n 1,777,005,178<\/p>\n
22 June 2026
\n 220,000
\n 291.32
\n 64,091,259<\/p>\n
23 June 2026
\n 210,000
\n 306.05
\n 64,269,567<\/p>\n
24 June 2026
\n 210,000
\n 309.81
\n 65,060,127<\/p>\n
25 June 2026
\n 210,000
\n 314.91
\n 66,131,566<\/p>\n
26 June 2026
\n 200,000
\n 311.46
\n 62,291,224<\/p>\n
Accumulated under the programme
\n 7,250,000
\n \u00a0
\n 2,098,848,921<\/p>\n
\u00a0<\/p>\n
The details for each transaction made under the share repurchase programme are published on novonordisk.com.<\/p>\n
\u00a0<\/p>\n
With the transactions stated
\nabove, Novo Nordisk owns a total of 39,194,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The
\ntotal amount of A and B shares in the company is 4,465,000,000 including treasury shares.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Page 2 of 2<\/p>\n
Novo Nordisk expects to repurchase B shares for an amount
\nup to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 26 June 2026, Novo Nordisk has since 4 February 2026 repurchased
\na total 22,009,179 B shares at an average share price of DKK 268.02 per B share equal to a transaction value of DKK 5,898,848,910.<\/p>\n
\u00a0<\/p>\n
Novo Nordisk is a leading global healthcare company founded in 1923
\nand headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes.
\nWe do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease.
\nNovo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are
\nlisted on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,
\nFacebook, Instagram, X, LinkedIn and YouTube.<\/p>\n
\u00a0<\/p>\n
Contacts
\nfor further information<\/p>\n
\u00a0<\/p>\n
Media:
\n \u00a0<\/p>\n
Ambre James-Brown
\n Liz Skrbkova
\n (US)<\/p>\n
+45 3079 9289
\n +1 609 917 0632<\/p>\n
globalmedia@novonordisk.com
\n \u00a0
\n lzsk@novonordisk.com<\/p>\n
\u00a0
\n \u00a0
\n \u00a0
\n \u00a0<\/p>\n
Investors:
\n \u00a0<\/p>\n
Michael Novod
\n Jacob Martin
\n Wiborg Rode<\/p>\n
+45 3075 6050
\n +45 3075 5956<\/p>\n
nvno@novonordisk.com
\n jrde@novonordisk.com<\/p>\n
\u00a0
\n \u00a0
\n \u00a0
\n \u00a0<\/p>\n
Ida Schaap Melvold
\n Sina Meyer<\/p>\n
+45 3077 5649
\n +45 3079 6656<\/p>\n
idmg@novonordisk.com
\n azey@novonordisk.com<\/p>\n
\u00a0
\n \u00a0
\n \u00a0
\n \u00a0<\/p>\n
Alex Bruce
\n Christoffer
\n Sho Togo Tullin<\/p>\n
+45 3444 2613
\n +45 3079 1471<\/p>\n
axeu@novonordisk.com
\n cftu@novonordisk.com<\/p>\n
\u00a0
\n \u00a0
\n \u00a0
\n \u00a0<\/p>\n
Frederik Taylor Pitter
\n Mads Berner
\n Bruun<\/p>\n
+1 609 613 0568
\n +45 3075 2936<\/p>\n
fptr@novonordisk.com
\n mbbz@novonordisk.com<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Novo Nordisk A\/S<\/p>\n
Investor Relations<\/p>\n
Novo All\u00e9 1<\/p>\n
2880 Bagsv\u00e6rd<\/p>\n
Denmark<\/p>\n
Telephone:<\/p>\n
+45 4444 8888<\/p>\n
www.novonordisk.com
CVR no: 24 25 67 90<\/p>\n
\u00a0\u00a0\u00a0Company
\nannouncement No 40\/ 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
\nduly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.<\/p>\n
\u00a0<\/p>\n
Date: June 29, 2026<\/p>\n
\u00a0<\/p>\n
NOVO NORDISK A\/S<\/p>\n
\u00a0<\/p>\n
Maziar Mike Doustdar<\/p>\n
Chief Executive Officer<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 ________________ \u00a0 FORM 6-K ________________ \u00a0 REPORT…\n","protected":false},"author":2,"featured_media":119052,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[26875,26873,272,3859,33320,26871,26872],"class_list":["post-119051","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-6-k-filing","tag-dkk-15-billion","tag-novo-nordisk","tag-nvo","tag-share-repurchase-programme","tag-stock-buyback","tag-treasury-shares"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116836958783997240","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/119051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=119051"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/119051\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/119052"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=119051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=119051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=119051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}